“������������������������������������������������r���:za33���”的搜索结果，显示 1-10 项，共有 1308 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (R/R) chronic lymphocytic leukemia (CLL). Hematology Electronic Consultations (e-Consults) the Mayo Clinic Experience. Jacksonville, Fla. The purpose of this ...

3. 血液科- 临床试验- 妙佑医疗国际

   ... (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (R/R) chronic lymphocytic leukemia (CLL). Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (R/R) multiple myeloma (MM). Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer, the ENHANCE Study.

7. 神经科- 临床试验- 妙佑医疗国际

   The purpose of this study is to measure target engagement in cerebrospinal fluid (CSF) and blood, and to establish the feasibility and safety of Dasatinib ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose ...